Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer ...
Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.
The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs) Reinforces position as first commercially approved contract development and manufacturing ...
If you describe the development of an antibody drug conjugate (ADC) in simple terms, you risk sounding as if you’re in an old Monty Python sketch, the one called “How to Do It,” which showed ...
TAMPA, Fla./LONDON - Akari Therapeutics, Plc (NASDAQ:AKTX) announced Tuesday the initiation of GMP manufacturing activities for AKTX-101, its lead antibody drug conjugate (ADC) program, partnering ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback